Exelixis, Inc. (EXEL) Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 27, 2024 (referred to as September 30, 2024). Exelixis is an oncology company focused on the discovery, development, and commercialization of medicines for difficult-to-treat cancers. Its primary revenue driver is the cabozantinib franchise (CABOMETYX and COMETRIQ), with a growing pipeline including the lead asset zanzalintinib.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenues | $539,542 | $471,920 | $1,601,946 | $1,350,556 |
| Net Product Revenues | $478,059 | $426,497 | $1,294,163 | $1,199,543 |
| License Revenues | $60,239 | $42,367 | $299,901 | $133,406 |
| Net Income | $117,973 | $1,041 | $381,406 | $122,247 |
| Diluted EPS | $0.40 | $0.00 | $1.28 | $0.38 |
| Operating Cash Flow (9M) | $459,708 | $322,753 | - | - |
| Cash & Marketable Securities | $1,712,582 | - | - | - |
| Working Capital | $1,155,372 | - | - | - |
Margins: Gross margin remained stable at 96% for both the three and nine-month periods ended September 30, 2024. The effective tax rate was 23.8% for Q3 2024 and 23.2% for the nine-month period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 14% in Q3 2024 and 19% for the nine months ended September 30, 2024, compared to the prior year. This was driven by a 12% increase in net product revenues (primarily CABOMETYX volume growth) and a 42% increase in license revenues.
- License Milestones: License revenues surged due to a $150.0 million commercial milestone from Ipsen (achieved in Q2, recognized in Q2/Q3) and a $12.5 million regulatory milestone from Ipsen in Q3.
- Expense Reduction: Research and development (R&D) expenses decreased 33% in Q3 2024 ($222.6M vs. $332.6M) and 17% for the nine-month period, largely due to lower license and collaboration costs and reduced drug discovery spending. Selling, general, and administrative (SG&A) expenses decreased 19% in Q3.
- Restructuring and Impairment: The company recognized a $51.7 million non-cash impairment charge related to long-lived assets (leased facilities) in Q3. Total restructuring expenses for the nine months ended September 30, 2024, were $33.4 million, substantially completed by the end of Q2.
- Profitability: The company reported a significant turnaround in profitability, with Net Income rising from $1.0 million in Q3 2023 to $118.0 million in Q3 2024.
Guidance, Outlook, and Risks
- Outlook: Management projects net product revenues may increase for the remainder of 2024 due to continued CABOMETYX volume growth. R&D and SG&A expenses are projected to decrease for the remainder of the year due to cost-saving initiatives and the 2024 Restructuring Plan.
- Pipeline Updates:
- CABOMETYX: FDA accepted an sNDA for pNET/epNET indications (PDUFA date: April 3, 2025). Ipsen opted into co-funding the CABINET study.
- Zanzalintinib: Enrollment completed for STELLAR-303 (CRC); ongoing for STELLAR-304 (RCC) and STELLAR-305 (SCCHN). A new collaboration with Merck was announced for SCCHN and RCC trials.
- Biotherapeutics: Initiated Phase 1 trial for XB010 (ADC). Discontinued development of XB002.
- Capital Allocation: In August 2024, the Board authorized a new $500 million stock repurchase program through the end of 2025. As of September 30, 2024, $487.6 million remained available.
- Risks and Contingencies:
- Patent Litigation: A favorable ruling was received in the MSN II litigation, blocking generic entry until at least January 15, 2030. However, a new ANDA was received from Sun Pharmaceutical Industries in September 2024, challenging patents expiring in 2032. Settlements with Teva and Cipla allow generic entry in 2031.
- Regulatory: The company qualified for the "small biotech" exception under the Inflation Reduction Act through 2026, delaying Medicare price negotiations.
Investor Verification Checklist
- Patent Expiry Dates: Verify the specific expiration dates of patents challenged in the Sun ANDA litigation and the potential impact of the MSN II appeal.
- Milestone Timing: Confirm the timing of future commercial and regulatory milestones from Ipsen and Takeda, which significantly impact quarterly revenue volatility.
- Restructuring Completion: Monitor the finalization of the 2024 Restructuring Plan and the realization of projected cost savings in R&D and SG&A.
- Pipeline Milestones: Track the PDUFA decision date for the CABOMETYX pNET/epNET indication (April 3, 2025) and enrollment progress for zanzalintinib Phase 3 trials.
- Stock Repurchases: Review the pace of share repurchases under the new $500 million authorization and its impact on diluted share count.